Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

@article{Lipton2012SuperiorityOD,
  title={Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.},
  author={Allan Lipton and Karim S Fizazi and Alison T Stopeck and David H. Henry and Janet Elizabeth Brown and Denise A Yardley and Gary E Richardson and Salvatore Siena and Pablo Maroto and Michael Clemens and Boris Bilynskyy and Veena Charu and Philippe Beuzeboc and Michael Rader and Mar{\'i}a Eugenia Ibarrar{\'a}n Viniegra and Fred Saad and Chunlei Ke and Ada Henrike Braun and Susie Jun},
  journal={European journal of cancer},
  year={2012},
  volume={48 16},
  pages={3082-92}
}
BACKGROUND Patients with bone metastases from advanced cancer often experience skeletal-related events (SRE), which cause substantial pain and morbidity. Denosumab, a fully human monoclonal antibody that inhibits RANK Ligand (RANKL), is a novel bone-targeted agent with a distinct mechanism of action relative to the bisphosphonate zoledronic acid, for prevention of SRE. This pre-planned analysis evaluates the efficacy and safety of denosumab versus zoledronic acid across three pivotal studies… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS
161 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 161 extracted citations

Similar Papers

Loading similar papers…